At the time of writing, Pacira BioSciences Inc [PCRX] stock is trading at $26.75, up 2.29%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PCRX shares have gain 14.32% over the last week, with a monthly amount glided 3.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on January 30, 2025, when Truist upgraded its rating to a Hold and also boosted its price target to $25 from $8. Previously, Truist downgraded its rating to Sell on August 13, 2024, and dropped its price target to $8. On August 12, 2024, downgrade downgraded it’s rating to Sector Perform and revised its price target to $14 on the stock. Raymond James downgraded its rating to a Mkt Perform. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $11 on August 12, 2024. JP Morgan downgraded its rating to Underweight for this stock on August 12, 2024, and downed its price target to $10. In a note dated July 03, 2024, Barclays downgraded an Equal Weight rating on this stock and revised its target price from $38 to $25.
For the past year, the stock price of Pacira BioSciences Inc fluctuated between $11.16 and $31.64. Currently, Wall Street analysts expect the stock to reach $32.33 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $26.75 at the most recent close of the market. An investor can expect a potential return of 20.86% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
According to Pacira BioSciences Inc [NASDAQ:PCRX], the company’s sales were 702.77M for trailing twelve months, which represents an 1.08% jump. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.1%, and Net Profit Margin reading is -0.15%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.13 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Pacira BioSciences Inc [NASDAQ:PCRX] has a current ratio of 2.41. As well, the Quick Ratio is 1.99, while the Cash Ratio is 0.9. Considering the valuation of this stock, the price to sales ratio is 1.76, the price to book ratio is 1.55.
Transactions by insiders
Recent insider trading involved GAUGLER DARYL, Officer, that happened on Mar 06 ’25 when 500.0 shares were purchased. Chief Medical Officer, SLONIN JONATHAN completed a deal on Jan 06 ’25 to sell 879.0 shares. Meanwhile, Officer SLONIN JONATHAN bought 879.0 shares on Jan 06 ’25.
